Sukhtian Faisal Ghiath 4
4 · Outlook Therapeutics, Inc. · Filed Oct 11, 2022
Insider Transaction Report
Form 4
Sukhtian Faisal Ghiath
Director
Transactions
- Purchase
Common Stock
2022-10-07$1.29/sh+30,000$38,700→ 68,000 total
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 - $1.295, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
- [F2]Reflects the amount of securities beneficially owned by the Reporting Person following the reported transaction herein and corrects the erroneous Form 4 filed with the Securities and Exchange Commission on April 22, 2022 (the "April 22, 2022 Filing"), pursuant to which a total of 55,816,786 shares were reported as indirectly beneficially owned (by GMS Ventures) on Table I. These shares are indirectly beneficially owned by Ghiath M. Sukhtian (CIK number 0001717441) and not by the Reporting Person. The April 22, 2022 Filing was erroneously made under the Reporting Person's CIK number.